<?xml version="1.0" encoding="UTF-8"?>
<ref id="R18">
 <label>18</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <string-name>
    <surname>Yao</surname>
    <given-names>Y</given-names>
   </string-name>, 
   <string-name>
    <surname>Higgs</surname>
    <given-names>BW</given-names>
   </string-name>, 
   <string-name>
    <surname>Richman</surname>
    <given-names>L</given-names>
   </string-name>, 
   <etal>et al</etal>
  </person-group>. 
  <article-title>Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNÎ± antibody, in systemic lupus erythematosus</article-title>. 
  <source>Arthritis Res Ther</source>
  <year>2010</year>;
  <volume>12 Suppl 1</volume>:
  <fpage>S6</fpage>. 
  <pub-id pub-id-type="doi">10.1186/ar2887</pub-id>
  <?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/20392292?>
  <pub-id pub-id-type="pmid">20392292</pub-id>
 </mixed-citation>
</ref>
